Taltz

Eli Lilly Builds Case to Expand Immune Drug’s Use to Spinal Arthritis
Eli Lilly Builds Case to Expand Immune Drug’s Use to Spinal Arthritis
Xconomy
Eli Lilly
Taltz
Flag link:
Eli Lilly touts PhIII success for Taltz as rival Novartis stays well out front in crowded immunology race
Eli Lilly touts PhIII success for Taltz as rival Novartis stays well out front in crowded immunology race
Endpoints
Eli Lilly
Taltz
Novartis
ankylosing spondylitis
Cosentyx
Flag link:
Lilly's 2018 forecast beats on strength of new drugs
Lilly's 2018 forecast beats on strength of new drugs
Yahoo/Reuters
Eli Lilly
Trulicity
Taltz
Flag link:
Lilly's Taltz takes Cosentyx rivalry into psoriatic arthritis with new FDA nod
Lilly's Taltz takes Cosentyx rivalry into psoriatic arthritis with new FDA nod
Fierce Pharma
Eli Lilly
Taltz
Novartis
Cosentyx
FDA
psoriatic arthritis
Flag link:
Humira may spend most on TV, but Xeljanz, Taltz and Breo notch highest view rates
Humira may spend most on TV, but Xeljanz, Taltz and Breo notch highest view rates
Fierce Pharma
Humira
Xeljanz
Taltz
Breo
drug ads
television ads
DTC ads
Flag link:
Novartis star Cosentyx, facing new rivals, may gain edge as a disease-modifying med
Novartis star Cosentyx, facing new rivals, may gain edge as a disease-modifying med
Fierce Pharma
Novartis
Cosentyx
psoriasis
Eli Lilly
Taltz
Valeant Pharmaceuticals
Siliq
Flag link:
Are DTC ads tipping the balance in psoriasis battle between Lilly’s Taltz and Novartis’ Cosentyx?
Are DTC ads tipping the balance in psoriasis battle between Lilly’s Taltz and Novartis’ Cosentyx?
Fierce Pharma
DTC advertising
psoriasis
Eli Lilly
Novartis
Taltz
Cosentyx
Flag link:
Eli Lilly’s new psoriasis treatment Taltz launches first ads, chasing Novartis’ Cosentyx lead
Eli Lilly’s new psoriasis treatment Taltz launches first ads, chasing Novartis’ Cosentyx lead
Fierce Pharma
Eli Lilly
psoriasis
Novartis
Cosentyx
Taltz
drug ads
Flag link: